There are also ways to help with fatigue, like:
- finding a good support system or group
- staying social and avoiding situations that make you feel lonely
- developing an exercise routine (and starting slowly)
Living with the symptoms of primary biliary cholangitis (PBC) isn’t easy, but here are some tips that can help.
Even if you’re not currently experiencing itching, you can still avoid situations that could cause your skin to itch. If do you experience pruritus while taking OCALIVA, talk to your healthcare provider. Then try working some of the following suggestions into your daily routine.
Pruritus can cause sleep deprivation. Patients also report that itching can become worse at night. Practicing good sleep habits and strategies can help improve sleep duration and quality.
Download the Managing Pruritus Brochure to get more tips to help manage symptoms of PBC.
Choose the discussion guide that best describes you to help you have the right conversation with your doctor.
Download a discussion guide:
Sign up for helpful tips, tools, and other materials to learn more about PBC and OCALIVA.
OCALIVA is a prescription medicine used to treat primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have not responded well enough to UDCA, or alone for adults who cannot tolerate UDCA. It is not known if taking OCALIVA will improve your chance of survival or improve your symptoms of PBC. It is not known if OCALIVA is safe and effective in children.
OCALIVA may cause serious side effects including:
Worsening of liver problems or liver failure, in some cases leading to liver transplant or death, has happened in people with primary biliary cholangitis (PBC) with liver cirrhosis when taking OCALIVA.
Before you start OCALIVA, and during your treatment with OCALIVA, your healthcare provider will do tests to check your liver. These tests will help your healthcare provider decide if it is safe for you to start taking OCALIVA and safe for you to continue taking OCALIVA.
Tell your healthcare provider right away if you have any of the following symptoms of worsening liver problems during treatment with OCALIVA:
Tell your healthcare provider right away if you have any of the following symptoms during treatment with OCALIVA and they are severe or do not go away:
Do not take OCALIVA if you:
OCALIVA may cause serious side effects, including:
The most common side effects of OCALIVA include: tiredness; stomach pain and discomfort; rash; joint pain; mouth and throat pain; dizziness; constipation; swelling in your hands, ankles, or feet; fast or irregular heartbeat; fever; changes in how your thyroid gland works; dryness, irritation, redness, crusting or drainage of the skin (eczema).
These are not all the possible side effects of OCALIVA. Call your doctor for medical advice about side effects.
Before taking OCALIVA, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over‑the‑counter medicines, vitamins, and herbal supplements. OCALIVA can affect the way certain medicines work. Certain other medicines may affect the way OCALIVA works.
The risk information provided here is not complete. To learn more, please talk to your healthcare provider.
Please click here for Full Prescribing Information and Medication Guide for OCALIVA.
Available by prescription only.
To report negative side effects of OCALIVA, please contact Intercept Pharmaceuticals, Inc. at 1-844-782-ICPT or you may report to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
OCALIVA® (obeticholic acid) is a prescription medicine used to treat primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have not responded well enough to UDCA, or alone for adults who cannot tolerate UDCA. It is not known if taking OCALIVA will improve your chance of survival or improve your symptoms of PBC. It is not known if OCALIVA is safe and effective in children.
Worsening of liver problems or liver failure, in some cases leading to liver transplant or death, has happened in people with primary biliary cholangitis (PBC) with liver cirrhosis when taking OCALIVA.